MK-8237

· ALK-Abelló A/S

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for MK-8237, covering 2017-02-13 to 2017-02-13. Get the full timeline:

Most recent: Clinical Trial Update: A Dose-Ranging Study of the Safety and Effectiveness of MK-8237 in the Treatment of House Dust Mite (HDM) Induced Allergic Rhinitis/Rhinoconjunctivitis in Adults (MK-8237-003/P07627) [Phase 2]

See pricing